Baysient
Developer of cloud-hosted clinical decision support software that uses Bayesian and pharmacokinetic models plus routine laboratory and demographic data to generate model-informed, individualized dosing recommendations for anti-inflammatory monoclonal antibody therapies. The company offers HIPAA-compliant SaaS intended for use by or under the supervision of healthcare professionals and reports prospective clinical validation of its precision-dosing approach.
Industries
Nr. of Employees
medium (51-250)
Services
SaaS that combines PK models, Bayesian updating, routine lab data and demographics to generate individualized dosing recommendations and forecasts for anti-inflammatory monoclonal antibody therapies.
Tools to forecast concentration-time profiles and simulate alternative dosing strategies, including route transitions (IV to subcutaneous) and pediatric/weight-based scenarios.
SaaS that combines PK models, Bayesian updating, routine lab data and demographics to generate individualized dosing recommendations and forecasts for anti-inflammatory monoclonal antibody therapies.
Tools to forecast concentration-time profiles and simulate alternative dosing strategies, including route transitions (IV to subcutaneous) and pediatric/weight-based scenarios.
Expertise Areas
- Model-informed precision dosing (MIPD)
- Pharmacokinetic (PK) modeling and Bayesian adaptive dosing
- Therapeutic drug monitoring (TDM)
- Clinical decision support (CDS) for biologics
Key Technologies
- Bayesian statistical models
- Pharmacokinetic (PK) modeling
- Model-informed precision dosing
- Therapeutic drug monitoring integration
News & Updates
Company representative presented on biologics and precision medicine in IBD at CDDW; scheduled attendance February 28 - March 1, 2020.
Blog article discussing application of PK-informed therapeutic drug monitoring to ustekinumab and how model-informed dosing applies to exposure-response relationships.
Press release describing release of version 1.0 for infliximab, clinical validation results (NCT02453776) showing reduction in switching, and details on HIPAA-compliant, EMR-compatible SaaS offering.
Reported 12-month clinical validation results (NCT02453776) with statistically significant improvement in outcomes (reported p = 0.017) and a claimed reduction in switching from infliximab to other biologics by 66% in the study cohort.
Company states certain time-to-target dosing and related software functionality are protected by patent.
Company representative presented on biologics and precision medicine in IBD at CDDW; scheduled attendance February 28 - March 1, 2020.
Blog article discussing application of PK-informed therapeutic drug monitoring to ustekinumab and how model-informed dosing applies to exposure-response relationships.
Press release describing release of version 1.0 for infliximab, clinical validation results (NCT02453776) showing reduction in switching, and details on HIPAA-compliant, EMR-compatible SaaS offering.
Reported 12-month clinical validation results (NCT02453776) with statistically significant improvement in outcomes (reported p = 0.017) and a claimed reduction in switching from infliximab to other biologics by 66% in the study cohort.
Company states certain time-to-target dosing and related software functionality are protected by patent.